BioSpace News Archive

CervoMed Inc., a clinical stage company focused on developing treatments for degenerative diseases of the brain, announced the publication of the following two articles that support advancing neflamapimod as a disease-modifying treatment for Dementia with Lewy Bodies and Alzheimer’s Disease :

Ginkgo Bioworks announced it is joining efforts with Penn State University to integrate its biosurveillance capabilities into the university’s research of 58 wildlife species for SARS-CoV-2 to monitor potential spillover to humans.

908 Devices Inc., a pioneer of handheld and desktop devices for chemical and biochemical analysis, announced it will report financial results for the third quarter 2023 before market open on Tuesday, November 7, 2023.

Bristol Myers Squibb announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 antagonist, for the treatment of progressive pulmonary fibrosis, a devastating, life-threatening illness.

Neurocentrx announced positive topline results from its Phase 1 clinical study of KET-IR, its novel oral ketamine immediate-release formulation to treat major mental health conditions, including treatment-resistant depression.

ZYUS Life Sciences Corporation, a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, is pleased to announce that Tim Miller is joining the Company as Director of Investor Relations and Capital Markets, effective November 1, 2023.

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher® test in patients with Barrett’s esophagus through two posters at the 2023 American College of Gastroenterology Annual Scientific Meeting, taking place Oct. 20-25, in Vancouver, Canada.

Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, announced positive interim results in its Phase 1b clinical study of UPB-101, a thymic stromal lymphopoietin receptor inhibitor.

Rampart Bioscience, Inc., a biotechnology company developing next-generation biologics, announced an $85 million Series A financing to create medicines that aim to unburden patients from disease and their treatments.

Moderna, Inc. announced that the first participant has been dosed in a Phase 3 study of the Company’s combination vaccine candidate against influenza and COVID-19 in the U.S. The trial is expected to enroll approximately 8,000 adults in the Northern Hemisphere.